natgillin/translations-raw huggingface dataset:
The MAH shall ensure that, following discussions and agreement with the National Competent Authorities in each Member State where Prometax patch is marketed, all physicians who are expected to prescribe Prometax patch are provided with an information pack containing the following elements: 
Imetnik dovoljenja za promet z zdravilom mora zagotoviti, da bodo po razpravi in pridobitvi soglasja nacionalnega pristojnega organa v vsaki državi članici, kjer je zdravilo Prometax obliž dostopno na trgu, vsi zdravniki, za katere se pričakuje, da bodo predpisovali zdravilo Prometax obliž, prejeli komplet navodil, ki bo vseboval sledeče:
- Each patch is sealed in its own protective sachet. 
Vsak obliž je zaprt v svojo zaščitno vrečko.
Can you wear your Prometax transdermal patch when you are bathing, swimming, or in the sun? 
Se sme transdermalni obliž Prometax nositi med kopanjem in plavanjem ter na soncu?
Clear, yellow solution. 
Bistra, rumena raztopina.
Your doctor will tell you which Prometax transdermal patch is most suitable for you. 
Zdravnik vam bo povedal, kateri transdermalni obliž Prometax je za vas najbolj primeren.
Hypersensitivity to the active substance rivastigmine, to other carbamate derivatives or to any of the excipients listed in section 6.1. 
Preobčutljivost na učinkovino rivastigmin, druge derivate karbamata ali katero koli pomožno snov, navedeno v poglavju 6.1.
Each box contains 28, 56 or 
Vsaka škatla vsebuje 28, 56 ali 112 kapsul.
Rivastigmine is weakly bound to plasma proteins (approximately 40%). 
Rivastigmin se šibko veže na beljakovine v plazmi (približno 40 %).
Parkinson's disease (worsening) 
Parkinsonova bolezen (poslabšanje)
Put the sticky side of the patch on the upper or lower back, upper arm or chest and then peel off the second side of the protective liner. 
Lepljivo stran obliža položite na zgornji ali spodnji del hrbta, nadlaket ali na prsi in nato odstranite drugo polovico zaščitne plasti.
30 transdermal patches. 
30 transdermalnih obližev.
Multipack: 60 (2 packs of 30) transdermal patches Multipack: 90 (3 packs of 30) transdermal patches 
Skupno pakiranje: 60 (2 pakiranji po 30) transdermalnih obližev Skupno pakiranje: 90 (3 pakiranja po 30) transdermalnih obližev
You may wish to experiment with different locations when applying a new patch, to find ones that are most comfortable for you and where clothing will not rub on the patch. 
Ko nameščate nove obliže, lahko preskušate različna mesta na koži, da bi ugotovili, katero vam je najbolj udobno in kje oblačila najmanj drgnejo kožo.
Prometax should not be given at the same time as other medicines with similar effects to Prometax. 
Zdravila Prometax ne smete jemati sočasno z drugimi zdravili, ki imajo podobne učinke kot zdravilo Prometax.
• Feeling tired or weak 
• občutek utrujenosti ali šibkosti
• Your doctor will slowly increase your dose depending on how you respond to treatment. 
• Zdravnik vam bo odmerek počasi zviševal glede na vaš odziv na zdravljenje.
Absolute bioavailability after a 3 mg dose is about 36%  13%. 
Absolutna biološka uporabnost po odmerku 3 mg je okrog 36 %  13 %.
Efficacy has been established by the use of two independent scales which were assessed at regular intervals during a 6-month treatment period as shown in Table 5 below: the ADAS-Cog, a measure of cognition, and the global measure ADCS-CGIC (Alzheimer's Disease Cooperative StudyClinician's Global Impression of Change). 
Učinkovitost so dokazali z uporabo dveh neodvisnih lestvic, s katerima so bolnike ocenjevali v rednih presledkih med 6-mesečnim obdobjem zdravljenja, kot kaže preglednica 5 spodaj: ADAS-Cog, merilo kognitivne zmogljivosti, in globalno merilo ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinician's Global Impression of Change /Kooperativna študija Alzheimerjeve bolezni-globalni klinični vtis sprememb).
The incidence of application site skin reactions leading to discontinuation was higher in the Asian population with 4.9% and 8.4% in the Chinese and Japanese population respectively. 
V azijski populaciji pa je bila pogostnost reakcij na mestu aplikacije, zaradi katerih je bilo treba zdravljenje prekiniti, večja - v kitajski populaciji je znašala 4,9 %, v japonski populaciji pa 8,4 %.
Based on CMH test (van Elteren test) blocking for country. 
Na podlagi testa CMH (van Elternovega testa) analize po kategorijah za posamezne države.
Rivastigmine transdermal patches were not phototoxic and considered to be a non-sensitiser. 
Transdermalni obliži z rivastigminom niso bili fototoksični in veljajo za obliže, ki ne povzročajo preobčutljivosti.
Uncommon (may affect up to 1 in 100 people) • Hyperactivity (high level of activity, restlessness) 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) • hiperaktivnost (povečana stopnja aktivnosti, nemir)
Every 24 hours take off the previous patch before putting ONE new patch on to ONLY ONE of the following possible locations. 
Vsakih 24 ur najprej odstranite prešnji obliž, nato pa namestite EN nov obliž na SAMO ENO od naslednjih možnih mest.
INTERMEDIATE CARTON OF MULTIPACK (WITHOUT BLUE BOX) 
VMESNA ŠKATLICA SKUPNEGA PAKIRANJA (BREZ "BLUE BOX" PODATKOV)
Prometax transdermal patches may cause fainting or severe confusion. 
Transdermalni obliži Prometax lahko povzročajo omedlevico ali hudo zmedenost.
These events led to the discontinuation of rivastigmine in some cases (e.g. discontinuations due to tremor 1.7% on rivastigmine vs 0% on placebo). 
Zaradi teh težav so v nekaterih primerih prekinili zdravljenje z rivastigminom (npr. z rivastigminom 1,7 % prekinitev zaradi tremorja v primerjavi z 0 % pri placebu).
• Tell your caregiver that you are taking Prometax. 
• Povejte svojemu negovalcu, da jemljete zdravilo Prometax.
• The patch should not be cut into pieces. 
• Obliža se ne sme rezati na manjše dele.
In view of its pharmacodynamic effects and possible additive effects, rivastigmine should not be given concomitantly with other cholinomimetic substances. 
Zaradi njegovih farmakodinamičnih učinkov in možnosti aditivnega delovanja se rivastigmina ne sme uporabljati skupaj z drugimi holinomimetičnimi snovmi.
• Severe confusion 
• huda zmedenost
Such events appeared to occur particularly after dose increments or high doses of rivastigmine. 
Do takih dogodkov je prišlo predvsem po povečevanju odmerka ali uporabi velikih odmerkov rivastigmina.
It was rated as severe in ≤2.2% of patients in these studies and in ≤3.7% of patients treated with Prometax transdermal patches in a Japanese study. 
V teh študijah so vnetje ocenili kot hudo pri ≤2,2 % bolnikov, v japonski študiji pa pri ≤3,7 % bolnikov, ki so se zdravili s transdermalnimi obliži Prometax.
In other cases, Prometax has been discontinued (see section 4.8). 
V drugih primerih so zdravilo Prometax ukinili (glejte poglavje 4.8).
• Stiff arms or legs 
• okorele roke ali noge
• Allergic reaction where the patch was used, such as blisters or skin inflammation If you get any of these side effects, contact your doctor as you may need medical assistance. 
• alergijske reakcije na mestu uporabe obliža, kot je pojav mehurjev ali vnete kože Če se pojavijo takšni neželeni učinki, obvestite svojega zdravnika, ker boste morda potrebovali zdravniško pomoč.
N is the number of patients with an assessment at baseline (last assessment in the initial openlabel phase) and with at least 1 post-baseline assessment (for the LOCF). 
N je število bolnikov, ki so opravili izhodiščno ocenjevanje (zadnje ocenjevanje v fazi odprtega zdravljenja) in še najmanj 1 ocenjevanje za tem (za vrednost, ki jo je mogoče uporabiti pri metodi LOCF)
Based on population analysis, creatinine clearance did not show any clear effect on steady state concentrations of rivastigmine or its metabolite. 
Po podatkih populacijske analize očistek kreatinina ni kazal jasnega učinka na koncentracije rivastigmina ali njegovih presnovkov v stanju dinamičnega ravnovesja.
Other medicines and Prometax 
Druga zdravila in zdravilo Prometax
• to patients predisposed to urinary obstruction and seizures because cholinomimetics may induce or exacerbate these diseases; 
• bolnikom, ki so nagnjeni k zapori sečnih izvodil in k epileptičnim napadom, ker holinomimetiki lahko sprožijo te bolezni ali njihovo poslabšanje;
What Prometax is and what it is used for 
Kaj je zdravilo Prometax in za kaj ga uporabljamo
The capsules and oral solution can also be used for the treatment of dementia in adult patients with Parkinson's disease. 
Kapsule in peroralno raztopino lahko uporabljamo tudi za zdravljenje demence pri odraslih bolnikih s Parkinsonovo boleznijo.
Your doctor will tell you what dose of Prometax to take. 
Zdravnik vam bo povedal, kakšen odmerek zdravila Prometax morate jemati.
• Apply ONE patch per day to ONLY ONE of the possible locations shown in the following diagrams: left upper arm or right upper arm left upper chest or right upper chest (avoid breast) left upper back or right upper back left lower back or right lower back 
• Namestite EN obliž na dan na SAMO ENO od možnih mest, ki so prikazana na naslednji skici: levi nadlaket ali desni nadlaket levi zgornji del prsi ali desni zgornji del prsi (ne na dojko) levi zgornji del hrbta ali desni zgornji del hrbta levi spodnji del hrbta ali desni spodnji del hrbta
• Trembling or feeling confused 
• tresenje ali občutek zmedenosti
• The patch should be replaced by a new one after 24 hours. 
• Obliž je treba po 24 urah zamenjati z novim.
• After removing a patch, fold it in half with the sticky sides on the inside and press them together. 
• Po odstranitvi obliža s kože ga prepognite na pol z lepljivo stranjo navznoter in stisnite.
Only one patch should be worn at a time (see section 4.9). 
Nameščen sme biti samo en obliž naenkrat (glejte poglavje 4.9).
If you have not taken Prometax for more than three days, do not take the next dose until you have talked to your doctor. 
Če zdravila Prometax niste jemali že več kot tri dni, ne vzemite naslednjega odmerka, dokler se ne pogovorite s svojim zdravnikom.
Misuse of the medicinal product and dosing errors with Prometax transdermal patch have resulted in serious adverse reactions; some cases have required hospitalisation, and rarely led to death (see section 4.9). 
Zaradi nepravilne uporabe in napak pri odmerjanju zdravila Prometax je prišlo do resnih neželenih učinkov; v nekaterih primerih je bila potrebna hospitalizacija, redko pa je prišlo do smrtnega izida (glejte poglavje 4.9).
• to patients with a history of asthma or obstructive pulmonary disease. 
• bolnikom z anamnezo astme ali obstruktivne pljučne bolezni.
Table 3 lists the number and percentage of patients from the specific 24-week clinical study conducted with Prometax in patients with dementia associated with Parkinson's disease with pre-defined adverse events that may reflect worsening of parkinsonian symptoms. 
Preglednica 3 navaja število in delež bolnikov iz specifične 24-tedenske klinične študije z zdravilom Prometax pri bolnikih z demenco, povezano s Parkinsonovo boleznijo, z vnaprej opredeljenimi neželenimi dogodki, ki lahko odražajo poslabšanje simptomov Parkinsonove bolezni.
• Fast or uneven heartbeat 
• hitro ali neenakomerno bitje srca
How to apply your Prometax transdermal patch Prometax patches are thin, opaque, plastic patches that stick to the skin. 
Kako namestiti transdermalni obliž Prometax Obliži Prometax so tanki neprozorni plastični obliži, ki jih prilepite na kožo.
times the maximum clinical exposure. 
4-krat večjem od največje klinične izpostavljenosti.
The patches are available in packs containing 7 or 30 sachets and in multipacks containing 60 or 90 sachets. 
Obliži so na voljo v pakiranju, ki vsebuje 7 ali 30 vrečk in v skupnem pakiranju, ki vsebuje 60 ali 90 vrečk.
Patients and their caregivers must be instructed on important administration instructions for Prometax transdermal patch (see section 4.2). 
Bolnike in njihove negovalce je treba opozoriti na pomembne napotke za uporabo transdermalnega obliža Prometax (glejte poglavje 4.2).
Prometax is used for the treatment of adult patients with mild to moderately severe Alzheimer's dementia, a progressive brain disorder that gradually affects memory, intellectual ability and behaviour. 
Zdravilo Prometax uporabljamo za zdravljenje odraslih bolnikov z blago do zmerno hudo Alzheimerjevo demenco, to je napredujoča bolezen možganov, ki postopoma prizadene spomin in intelektualne sposobnosti ter vpliva na vedenje bolnika.
Prior to launch in each Member State the Marketing Authorisation Holder (MAH) shall agree the final educational material with the National Competent Authority. 
Pred prihodom zdravila na trg mora imetnik dovoljenja za promet z zdravilom v vsaki državi članici od nacionalnega pristojnega organa pridobiti soglasje za izobraževalno gradivo.
• Swallow your medicine straight from the syringe. 
• Zdravilo zaužijte naravnost iz brizge.
If you stop using Prometax Tell your doctor or pharmacist if you stop using the patch. 
Če ste prenehali uporabljati zdravilo Prometax Svojemu zdravniku povejte, če ste prenehali uporabljati obliže.
Switching from capsules or oral solution to transdermal patches Based on comparable exposure between oral and transdermal rivastigmine (see section 5.2), patients treated with Prometax capsules or oral solution can be switched to Prometax transdermal patches as follows: 
Prehod z zdravljenja s kapsulami ali peroralno raztopino na zdravljenje z obliži Glede na to, da je izpostavljenost rivastigminu primerljiva pri peroralni in transdermalni aplikaciji (glejte poglavje 5.2), lahko bolniki, ki se zdravijo s kapsulami ali peroralno raztopino Prometax, preidejo na zdravljenje s transdermalnimi obliži Prometax na naslednji način:
Patients and caregivers should be instructed on important administration instructions: 
Bolnike in negovalce je treba opozoriti na pomembne napotke za uporabo zdravila:
It is recommended to apply the first transdermal patch on the day following the last oral dose. 
Prvi transdermalni obliž je priporočljivo namestiti na dan, ki sledi dnevu zadnjega peroralnega odmerka.
• Hepatic impairment: Patients with clinically significant hepatic impairment may experience more adverse reactions. 
• Okvara jeter: Pri bolnikih s klinično pomembno okvaro jeter je lahko število neželenih učinkov večje.
If this applies to you, tell your doctor and do not take Prometax. 
Če kaj od navedenega velja za vas, povejte svojemu zdravniku in ne jemljite zdravila Prometax.
[folding box only] 
[samo na škatli]
• Feeling agitated or sleepy 
• občutek vznemirjenosti ali zaspanost
The 48-week results for the two assessment tools are summarised in Table 4. 
48-tedenski rezultati teh dveh metod ocenjevanja so zbrani v preglednici 4.
Less than 1% of the administered dose is excreted in the faeces. 
Manj kot 1 % apliciranega odmerka se izloči z blatom.
The efficacy of rivastigmine in dementia associated with Parkinson's disease has been demonstrated in a 24-week multicentre, double-blind, placebo-controlled core study and its 24-week open-label extension phase. 
Učinkovitost rivastigmina pri demenci, povezani s Parkinsonovo boleznijo, so pokazali v 24-tedenski multicentrični, dvojno slepi, s placebom kontrolirani osnovni študiji in njeni 24-tedenski odprti podaljšani fazi.
Available in packs containing 7 or 30 sachets and in multipacks containing 60 or 90 sachets. 
Na voljo so v pakiranju, ki vsebuje 7 ali 30 vrečk, in v skupnem pakiranju, ki vsebuje 60 ali 90 vrečk.
In two 24-week double-blind, placebo-controlled clinical trials, skin reactions were measured at each visit using a skin irritation rating scale. 
V dveh 24-tedenskih dvojno slepih, s placebom kontroliranih kliničnih študijah so kožne reakcije pri vsakem obisku merili s pomočjo lestvice za oceno kožnega vnetja.
However, these events did not occur at a higher frequency with Prometax 13.3 mg/24 h transdermal patches than with placebo. 
Vendar pa se ti dogodki niso pojavljali pogosteje pri uporabi transdermalnega obliža Prometax 13,3 mg/24 h v primerjavi s placebom.
Peel off one side of the protective liner and do not touch the sticky part of the patch with the fingers. 
Najprej odstranite eno polovico zaščitne plasti in se pri tem s prsti ne dotikajte lepljivega dela obliža.
• Hepatic impairment: Due to increased exposure in mild to moderate hepatic impairment as observed with the oral formulation, dosing recommendations to titrate according to individual tolerability should be closely followed. 
• Okvara jeter: Zaradi povečane izpostavljenosti zdravilu pri blagi do zmerni okvari jeter, kar so opažali pri uporabi peroralnih oblik zdravila, se je treba natančno ravnati po priporočilih, naj se odmerjanje titrira glede na individualno prenašanje.
Like all medicines, Prometax transdermal patches can cause side effects, although not everybody gets them. 
Kot vsa zdravila imajo lahko tudi transdermalni obliži Prometax neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
Prometax 9 mg/5 cm 2, 18 mg/10 cm and 27 mg/15 cm transdermal patches are individually packaged in child-resistant, heat-sealed sachets made of a paper/polyethyleneterephthalate/aluminum/polyacrylnitrile (PAN) multi-laminated material (paper/PET/alu/PAN) or in heat-sealed, child-resistant sachets made of multi-layer composite laminate consisting of paper/polyethylene terephthalate/polyethylene/aluminum/polyamide (paper/PET/PE/alu/PA). 
Transdermalni obliži Prometax jakosti 9 mg/5 cm 2, 18 mg/10 cm in 27 mg/15 cm so posamično pakirani v za otroke varne, toplotno zavarjene vrečke, narejene iz multilaminatnega materiala iz papirja/polietilen tereftalata/aluminija/poliakrilonitrila (PAN) (papir/PET/alu/PAN) ali v toplotno zavarjene, za otroke varne vrečke, narejene iz večplastne kompozitne folije iz papirja/polietilen tereftalata/polietilena/aluminija/poliamida (papir/PET/PE/alu/PA).
• The recommended usual daily dose is Prometax 9.5 mg/24 h. If well tolerated, the treating physician may consider increasing the dose to 13.3 mg/24 h. 
• Priporočeni običajni dnevni odmerek zdravila Prometax je 9,5 mg/24 h. Če ta odmerek dobro prenašate, lahko lečeči zdravnik razmisli o zvišanju odmerka na 13,3 mg/24 h.
When normalised to body surface area, the exposure to rivastigmine and its metabolites was approximately equivalent to the maximum recommended human dose of 12 mg/day; however, when compared to the maximum human dose, a multiple of approximately 6-fold was achieved in animals. 
Izpostavljenost rivastigminu in njegovim presnovkom, preračunana na telesno površino, je bila približno enakovredna največjemu priporočenemu odmerku za ljudi 12 mg/dan; vendar je bil v primerjavi z največjim odmerkom za ljudi dosežen pri živalih približno njegov 6-kratni mnogokratnik.
- HDPE bottles with plastic closure with induction innerseal. 
- Steklenice iz HDPE s plastično zaporko z zaščitno folijo.
Care must be taken when prescribing Prometax transdermal patches: 
Previdnost je potrebna pri predpisovanju transdermalnih obližev Prometax:
• Wipe the outside of the syringe with a clean tissue. 
• Zunanjost brizge obrišite s čisto krpo.
Discontinuation should also be considered when evidence of a therapeutic effect at the optimal dose is no longer present. 
O prekinitvi zdravljenja je treba razmisliti tudi v primeru, da pri uporabi optimalnega odmerka ni več znakov terapevtskih koristi.
If this applies to you, tell your doctor and do not apply Prometax transdermal patches. 
Če kaj od navedenega velja za vas, povejte svojemu zdravniku in ne uporabljajte transdermalnih obližev Prometax.
• Take Prometax twice a day, in the morning and evening, with food. 
• Zdravilo Prometax jemljite s hrano dvakrat na dan, zjutraj in zvečer.
ITT - LOCF population (n=287) 
Skupina ITT - LOCF (n=287)
Table 2 shows the adverse reactions reported during clinical studies conducted in patients with dementia associated with Parkinson's disease treated with Prometax capsules. 
Preglednica 2 prikazuje neželene učinke, o katerih so poročali iz kliničnih študij, ki so jih izvajali pri bolnikih z demenco, povezano s Parkinsonovo boleznijo, zdravljenih s kapsulami zdravila Prometax.
Absorption of rivastigmine from Prometax transdermal patches is slow. 
Rivastigmin se iz transdermalnih obližev Prometax absorbira počasi.
• Only wear one Prometax patch at a time and replace the patch with a new one after 24 hours. 
• Nosite samo en transdermalni obliž Prometax naenkrat in ga po 24 urah zamenjajte z novim.
• Treatment usually starts with Prometax 4.6 mg/24 h. 
• Zdravljenje se običajno začne z obližem Prometax 4,6 mg/24 h.
Some people who have accidentally taken too much Prometax have experienced feeling sick (nausea), being sick (vomiting), diarrhoea, high blood pressure and hallucinations. 
Pri nekaterih ljudeh, ki so nehote vzeli preveč zdravila Prometax, je prišlo do navzee (slabosti s siljenjem na bruhanje), bruhanja, driske, visokega krvnega tlaka in halucinacij.
Prometax may cause dizziness and somnolence, mainly at the start of treatment or when increasing the dose. 
Zdravilo Prometax lahko povzroči vrtoglavost in zaspanost, predvsem na začetku zdravljenja ali ob povečanju odmerka.
• Instructions to provide patients and caregivers with the patient reminder card 
• navodila za izročanje opozorilne kartice za bolnika bolnikom in negovalcem.
If you accidentally apply more than one patch, remove all the patches from your skin, then inform your doctor that you have accidentally applied more than one patch. 
Če ste uporabili večji odmerek zdravila Prometax, kot bi smeli Če ste nehote namestili več kot en obliž, odstranite s kože vse obliže in obvestite zdravnika, da ste nehote namestili več kot en obliž.
If you have not applied a patch for more than three days, do not apply the next one before you have talked to your doctor. 
Če obliža niste namestili kot tri dni, ne nameščajte naslednjega, dokler se ne pogovorite s svojim zdravnikom.
By blocking these enzymes, Prometax allows levels of acetylcholine to be increased in the brain, helping to reduce the symptoms of Alzheimer's disease. 
Zdravilo Prometax z zaviranjem navedenih encimov omogoča zvišanje koncentracije acetilholina v možganih in s tem pomaga pri zmanjševanju simptomov Alzheimerjeve bolezni.
If you have to undergo surgery whilst using Prometax transdermal patches, tell your doctor that you are using them because they may exaggerate the effects of some muscle relaxants during anaesthesia. 
Če morate v času uporabe transdermalnih obližev Prometax na operacijo, morate obvestiti zdravnika, da jih uporabljate, ker lahko med anestezijo povečajo učinke nekaterih mišičnih relaksantov.
Prometax might interfere with anticholinergic medicines (medicines used to relieve stomach cramps or spasms, to treat Parkinson's disease or to prevent travel sickness). 
Zdravilo Prometax bi lahko vplivalo na zdravljenje z antiholinergičnimi zdravili (zdravili, ki se uporabljajo za lajšanje želodčnih krčev ali spazmov, za zdravljenje Parkinsonove bolezni ali za preprečevanje slabosti na potovanju).
• Allergic reaction where the patch was used, such as blisters or inflamed skin 
• alergijske reakcije na mestu uporabe obliža, kot je pojav mehurjev ali vnete kože
Most cases of accidental overdose have not been associated with any clinical signs or symptoms and almost all of the patients concerned continued rivastigmine treatment 24 hours after the overdose. 
Večina primerov nenamernega prevelikega odmerjanja ni bila povezana z nikakršnimi kliničnimi znaki ali simptomi in skoraj vsi ti bolniki so nadaljevali zdravljenje z rivastigminom 24 ur po prevelikem odmerjanju.
In double-blind controlled clinical trials, application site reactions were mostly mild to moderate in severity. 
V dvojno slepih kontroliranih kliničnih študijah so bile reakcije na mestu aplikacije večinoma le blago do zmerno izražene.
Based on in vitro studies, no pharmacokinetic interaction is expected with medicinal products metabolised by the following cytochrome isoenzymes: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19, or CYP2B6. 
Po podatkih raziskav in vitro ni pričakovati farmakokinetičnih interakcij z zdravili, ki jih presnavljajo naslednji izoencimi s citokromi: CYP1A2, CYP2D6, CYP3A4/5, CYP2E1, CYP2C9, CYP2C8, CYP2C19 in CYP2B6.